Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 1
2004 5
2005 8
2006 7
2007 9
2008 15
2009 9
2010 13
2011 16
2012 6
2013 11
2014 15
2015 17
2016 15
2017 18
2018 19
2019 12
2020 19
2021 17
2022 16
2023 7
2024 6
2025 9
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

253 results

Results by year

Filters applied: . Clear all
Page 1
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Paik PK, et al. Among authors: van meerbeeck j. N Engl J Med. 2020 Sep 3;383(10):931-943. doi: 10.1056/NEJMoa2004407. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469185 Free PMC article. Clinical Trial.
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F; CONVERT Study Team. Faivre-Finn C, et al. Among authors: van meerbeeck jp. Lancet Oncol. 2017 Aug;18(8):1116-1125. doi: 10.1016/S1470-2045(17)30318-2. Epub 2017 Jun 20. Lancet Oncol. 2017. PMID: 28642008 Free PMC article. Clinical Trial.
Lung Cancer in Belgium.
Ocak S, Tournoy K, Berghmans T, Demedts I, Durieux R, Janssens A, Moretti L, Nackaerts K, Pieters T, Surmont V, Van Eycken L, Vrijens F, Weynand B, van Meerbeeck JP. Ocak S, et al. Among authors: van meerbeeck jp. J Thorac Oncol. 2021 Oct;16(10):1610-1621. doi: 10.1016/j.jtho.2021.07.022. J Thorac Oncol. 2021. PMID: 34561034 Free article. No abstract available.
Rebuttal from Dr van Meerbeeck.
van Meerbeeck JP. van Meerbeeck JP. Transl Lung Cancer Res. 2015 Aug;4(4):485-6. doi: 10.3978/j.issn.2218-6751.2015.07.08. Transl Lung Cancer Res. 2015. PMID: 26380193 Free PMC article. No abstract available.
Raltitrexed in mesothelioma.
Surmont VF, van Meerbeeck JP. Surmont VF, et al. Among authors: van meerbeeck jp. Expert Rev Anticancer Ther. 2011 Oct;11(10):1481-90. doi: 10.1586/era.11.136. Expert Rev Anticancer Ther. 2011. PMID: 21999120 Review.
Small-cell lung cancer.
van Meerbeeck JP, Fennell DA, De Ruysscher DK. van Meerbeeck JP, et al. Lancet. 2011 Nov 12;378(9804):1741-55. doi: 10.1016/S0140-6736(11)60165-7. Epub 2011 May 10. Lancet. 2011. PMID: 21565397 Review.
Editorial: Imaging assessment of response to immunotherapy.
Occhipinti M, Filippi AR, Walsh S, van Meerbeeck JP. Occhipinti M, et al. Among authors: van meerbeeck jp. Front Oncol. 2023 Jan 20;12:1116315. doi: 10.3389/fonc.2022.1116315. eCollection 2022. Front Oncol. 2023. PMID: 36741725 Free PMC article. No abstract available.
Co-targeting of VEGFR2 and PD-L1 promotes survival and vasculature normalization in pleural mesothelioma.
Rovers S, Van Audenaerde J, Verloy R, De Waele J, Brants L, Hermans C, Lau HW, Merlin C, Möller Ribas M, Ponsaerts P, Van Laere S, Lardon F, Wouters A, Fisher SA, van Meerbeeck J, Marcq E, Smits E. Rovers S, et al. Among authors: van meerbeeck j. Oncoimmunology. 2025 Dec;14(1):2512104. doi: 10.1080/2162402X.2025.2512104. Epub 2025 May 29. Oncoimmunology. 2025. PMID: 40439143 Free PMC article.
Lung cancer in Europe: The way forward.
Racovita M, Wheeler E, Wait S, Bancroft D, Eastabrook R, Albreht T, Baird AM, Jassem J, McNamara A, Novello S, Radu-Loghin C, van Meerbeeck JP. Racovita M, et al. Among authors: van meerbeeck jp. Tob Prev Cessat. 2022 Feb 15;8:06. doi: 10.18332/tpc/146645. eCollection 2022. Tob Prev Cessat. 2022. PMID: 35233474 Free PMC article. No abstract available.
Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 study.
Aerts JG, Belderbos R, Baas P, Scherpereel A, Bezemer K, Enninga I, Meijer R, Willemsen M, Berardi R, Fennell D, Kerstens R, Cornelissen R, van Meerbeeck JP; DENIM team. Aerts JG, et al. Among authors: van meerbeeck jp. Lancet Oncol. 2024 Jul;25(7):865-878. doi: 10.1016/S1470-2045(24)00191-8. Epub 2024 Jun 4. Lancet Oncol. 2024. PMID: 38848742 Clinical Trial.
253 results